Global Tumor Targeting Peptides 麻豆原创 Growth 2024-2030

Publication ID:

LPI11240897

Publication Date:

November 5, 2024

Pages:

116

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Tumor Targeting Peptides are short peptides that can specifically recognize and bind to specific receptors or antigens on the surface of tumor cells. These peptides can be used for diagnosis, treatment and imaging of tumors because they have high specificity and affinity, can effectively target tumor cells and reduce damage to normal cells.
The global Tumor Targeting Peptides market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淭umor Targeting Peptides Industry Forecast鈥� looks at past sales and reviews total world Tumor Targeting Peptides sales in 2023, providing a comprehensive analysis by region and market sector of projected Tumor Targeting Peptides sales for 2024 through 2030. With Tumor Targeting Peptides sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Targeting Peptides industry.
This Insight Report provides a comprehensive analysis of the global Tumor Targeting Peptides landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Targeting Peptides portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Tumor Targeting Peptides market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Targeting Peptides and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Targeting Peptides.
United States market for Tumor Targeting Peptides is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Tumor Targeting Peptides is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Tumor Targeting Peptides is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Tumor Targeting Peptides players cover Cayman Chemical, Danaher(Abcam), Selleck Chemicals, Cell Guidance Systems, RayBiotech, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Targeting Peptides market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Therapeutic Targeting Peptides
Imaging Targeting Peptides
Segmentation by Application:
Scientific Research
Pharmaceuticals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Cayman Chemical
Danaher(Abcam)
Selleck Chemicals
Cell Guidance Systems
RayBiotech
Merck KGaA
PEPTIDE INSTITUTE
Bachem
ASIA BIOSCIENCE CO
Biorbyt
CPC Scientific Inc
Advanced ChemTech
TargetMol Chemicals
QYAOBIO
Key Questions Addressed in this Report
What is the 10-year outlook for the global Tumor Targeting Peptides market?
What factors are driving Tumor Targeting Peptides market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tumor Targeting Peptides market opportunities vary by end market size?
How does Tumor Targeting Peptides break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Tumor Targeting Peptides Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Tumor Targeting Peptides by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Tumor Targeting Peptides by Country/Region, 2019, 2023 & 2030
2.2 Tumor Targeting Peptides Segment by Type
2.2.1 Therapeutic Targeting Peptides
2.2.2 Imaging Targeting Peptides
2.3 Tumor Targeting Peptides Sales by Type
2.3.1 Global Tumor Targeting Peptides Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Tumor Targeting Peptides Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Tumor Targeting Peptides Sale Price by Type (2019-2024)
2.4 Tumor Targeting Peptides Segment by Application
2.4.1 Scientific Research
2.4.2 Pharmaceuticals
2.5 Tumor Targeting Peptides Sales by Application
2.5.1 Global Tumor Targeting Peptides Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Tumor Targeting Peptides Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Tumor Targeting Peptides Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Tumor Targeting Peptides Breakdown Data by Company
3.1.1 Global Tumor Targeting Peptides Annual Sales by Company (2019-2024)
3.1.2 Global Tumor Targeting Peptides Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Tumor Targeting Peptides Annual Revenue by Company (2019-2024)
3.2.1 Global Tumor Targeting Peptides Revenue by Company (2019-2024)
3.2.2 Global Tumor Targeting Peptides Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Tumor Targeting Peptides Sale Price by Company
3.4 Key Manufacturers Tumor Targeting Peptides Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumor Targeting Peptides Product Location Distribution
3.4.2 Players Tumor Targeting Peptides Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Tumor Targeting Peptides by Geographic Region
4.1 World Historic Tumor Targeting Peptides 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Tumor Targeting Peptides Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Tumor Targeting Peptides Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Tumor Targeting Peptides 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Tumor Targeting Peptides Annual Sales by Country/Region (2019-2024)
4.2.2 Global Tumor Targeting Peptides Annual Revenue by Country/Region (2019-2024)
4.3 Americas Tumor Targeting Peptides Sales Growth
4.4 APAC Tumor Targeting Peptides Sales Growth
4.5 Europe Tumor Targeting Peptides Sales Growth
4.6 Middle East & Africa Tumor Targeting Peptides Sales Growth
5 Americas
5.1 Americas Tumor Targeting Peptides Sales by Country
5.1.1 Americas Tumor Targeting Peptides Sales by Country (2019-2024)
5.1.2 Americas Tumor Targeting Peptides Revenue by Country (2019-2024)
5.2 Americas Tumor Targeting Peptides Sales by Type (2019-2024)
5.3 Americas Tumor Targeting Peptides Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Targeting Peptides Sales by Region
6.1.1 APAC Tumor Targeting Peptides Sales by Region (2019-2024)
6.1.2 APAC Tumor Targeting Peptides Revenue by Region (2019-2024)
6.2 APAC Tumor Targeting Peptides Sales by Type (2019-2024)
6.3 APAC Tumor Targeting Peptides Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Tumor Targeting Peptides by Country
7.1.1 Europe Tumor Targeting Peptides Sales by Country (2019-2024)
7.1.2 Europe Tumor Targeting Peptides Revenue by Country (2019-2024)
7.2 Europe Tumor Targeting Peptides Sales by Type (2019-2024)
7.3 Europe Tumor Targeting Peptides Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor Targeting Peptides by Country
8.1.1 Middle East & Africa Tumor Targeting Peptides Sales by Country (2019-2024)
8.1.2 Middle East & Africa Tumor Targeting Peptides Revenue by Country (2019-2024)
8.2 Middle East & Africa Tumor Targeting Peptides Sales by Type (2019-2024)
8.3 Middle East & Africa Tumor Targeting Peptides Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumor Targeting Peptides
10.3 Manufacturing Process Analysis of Tumor Targeting Peptides
10.4 Industry Chain Structure of Tumor Targeting Peptides
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumor Targeting Peptides Distributors
11.3 Tumor Targeting Peptides Customer
12 World Forecast Review for Tumor Targeting Peptides by Geographic Region
12.1 Global Tumor Targeting Peptides 麻豆原创 Size Forecast by Region
12.1.1 Global Tumor Targeting Peptides Forecast by Region (2025-2030)
12.1.2 Global Tumor Targeting Peptides Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Tumor Targeting Peptides Forecast by Type (2025-2030)
12.7 Global Tumor Targeting Peptides Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Cayman Chemical
13.1.1 Cayman Chemical Company Information
13.1.2 Cayman Chemical Tumor Targeting Peptides Product Portfolios and Specifications
13.1.3 Cayman Chemical Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Cayman Chemical Main Business Overview
13.1.5 Cayman Chemical Latest Developments
13.2 Danaher(Abcam)
13.2.1 Danaher(Abcam) Company Information
13.2.2 Danaher(Abcam) Tumor Targeting Peptides Product Portfolios and Specifications
13.2.3 Danaher(Abcam) Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Danaher(Abcam) Main Business Overview
13.2.5 Danaher(Abcam) Latest Developments
13.3 Selleck Chemicals
13.3.1 Selleck Chemicals Company Information
13.3.2 Selleck Chemicals Tumor Targeting Peptides Product Portfolios and Specifications
13.3.3 Selleck Chemicals Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Selleck Chemicals Main Business Overview
13.3.5 Selleck Chemicals Latest Developments
13.4 Cell Guidance Systems
13.4.1 Cell Guidance Systems Company Information
13.4.2 Cell Guidance Systems Tumor Targeting Peptides Product Portfolios and Specifications
13.4.3 Cell Guidance Systems Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Cell Guidance Systems Main Business Overview
13.4.5 Cell Guidance Systems Latest Developments
13.5 RayBiotech
13.5.1 RayBiotech Company Information
13.5.2 RayBiotech Tumor Targeting Peptides Product Portfolios and Specifications
13.5.3 RayBiotech Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 RayBiotech Main Business Overview
13.5.5 RayBiotech Latest Developments
13.6 Merck KGaA
13.6.1 Merck KGaA Company Information
13.6.2 Merck KGaA Tumor Targeting Peptides Product Portfolios and Specifications
13.6.3 Merck KGaA Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Merck KGaA Main Business Overview
13.6.5 Merck KGaA Latest Developments
13.7 PEPTIDE INSTITUTE
13.7.1 PEPTIDE INSTITUTE Company Information
13.7.2 PEPTIDE INSTITUTE Tumor Targeting Peptides Product Portfolios and Specifications
13.7.3 PEPTIDE INSTITUTE Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 PEPTIDE INSTITUTE Main Business Overview
13.7.5 PEPTIDE INSTITUTE Latest Developments
13.8 Bachem
13.8.1 Bachem Company Information
13.8.2 Bachem Tumor Targeting Peptides Product Portfolios and Specifications
13.8.3 Bachem Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Bachem Main Business Overview
13.8.5 Bachem Latest Developments
13.9 ASIA BIOSCIENCE CO
13.9.1 ASIA BIOSCIENCE CO Company Information
13.9.2 ASIA BIOSCIENCE CO Tumor Targeting Peptides Product Portfolios and Specifications
13.9.3 ASIA BIOSCIENCE CO Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 ASIA BIOSCIENCE CO Main Business Overview
13.9.5 ASIA BIOSCIENCE CO Latest Developments
13.10 Biorbyt
13.10.1 Biorbyt Company Information
13.10.2 Biorbyt Tumor Targeting Peptides Product Portfolios and Specifications
13.10.3 Biorbyt Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Biorbyt Main Business Overview
13.10.5 Biorbyt Latest Developments
13.11 CPC Scientific Inc
13.11.1 CPC Scientific Inc Company Information
13.11.2 CPC Scientific Inc Tumor Targeting Peptides Product Portfolios and Specifications
13.11.3 CPC Scientific Inc Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 CPC Scientific Inc Main Business Overview
13.11.5 CPC Scientific Inc Latest Developments
13.12 Advanced ChemTech
13.12.1 Advanced ChemTech Company Information
13.12.2 Advanced ChemTech Tumor Targeting Peptides Product Portfolios and Specifications
13.12.3 Advanced ChemTech Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Advanced ChemTech Main Business Overview
13.12.5 Advanced ChemTech Latest Developments
13.13 TargetMol Chemicals
13.13.1 TargetMol Chemicals Company Information
13.13.2 TargetMol Chemicals Tumor Targeting Peptides Product Portfolios and Specifications
13.13.3 TargetMol Chemicals Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 TargetMol Chemicals Main Business Overview
13.13.5 TargetMol Chemicals Latest Developments
13.14 QYAOBIO
13.14.1 QYAOBIO Company Information
13.14.2 QYAOBIO Tumor Targeting Peptides Product Portfolios and Specifications
13.14.3 QYAOBIO Tumor Targeting Peptides Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 QYAOBIO Main Business Overview
13.14.5 QYAOBIO Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.